In the present study, therefore, we examined whether a small dose of G-CSF (10 μg/kg/day) of which administration was begun 1 day after coronary occlusion could beneficially affect post-infarction cardiac function at the chronic stage (4 weeks after MI). The gene discussed is CSF3; the disease is myocardial infarction.